These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

198 related articles for article (PubMed ID: 37496817)

  • 1. Factors associated with the response to atezolizumab/bevacizumab combination therapy for hepatocellular carcinoma.
    Yano Y; Yamamoto A; Mimura T; Kushida S; Hirohata S; Yoon S; Hirano H; Kim SK; Hatazawa Y; Momose K; Hayashi H; Kado T; Nishi K; Tanaka H; Matsuura T; Yoshida R; Asaji N; Yasutomi E; Shiomi Y; Minami A; Komatsu S; Fukumoto T; Ueda Y; Kodama Y
    JGH Open; 2023 Jul; 7(7):476-481. PubMed ID: 37496817
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Atezolizumab Plus Bevacizumab in Patients with Advanced and Progressing Hepatocellular Carcinoma: Retrospective Multicenter Experience.
    Sinner F; Pinter M; Scheiner B; Ettrich TJ; Sturm N; Gonzalez-Carmona MA; Waidmann O; Finkelmeier F; Himmelsbach V; De Toni EN; Ben Khaled N; Mohr R; Fründt TW; Kütting F; Bömmel FV; Lieb S; Krug S; Bettinger D; Schultheiß M; Jochheim LS; Best J; Müller C; Keitel V; Venerito M
    Cancers (Basel); 2022 Dec; 14(23):. PubMed ID: 36497447
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Changes in ALBI Score and PIVKA-II within Three Months after Commencing Atezolizumab Plus Bevacizumab Treatment Affect Overall Survival in Patients with Unresectable Hepatocellular Carcinoma.
    Unome S; Imai K; Takai K; Miwa T; Hanai T; Nishigaki Y; Hayashi H; Kochi T; Shimizu S; Nagano J; Iritani S; Suetsugu A; Shimizu M
    Cancers (Basel); 2022 Dec; 14(24):. PubMed ID: 36551574
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Albumin-Bilirubin Grade Analyses of Atezolizumab plus Bevacizumab versus Sorafenib in Patients with Unresectable Hepatocellular Carcinoma: A Post Hoc Analysis of the Phase III IMbrave150 Study.
    Kudo M; Finn RS; Cheng AL; Zhu AX; Ducreux M; Galle PR; Sakamoto N; Kato N; Nakano M; Jia J; Vogel A
    Liver Cancer; 2023 Oct; 12(5):479-493. PubMed ID: 37901766
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pretreatment Modified Albumin-Bilirubin Grade Is an Important Predictive Factor Associated with the Therapeutic Response and the Continuation of Atezolizumab plus Bevacizumab Combination Therapy for Patients with Unresectable Hepatocellular Carcinoma.
    Tanaka T; Takata K; Yokoyama K; Fukuda H; Yamauchi R; Fukunaga A; Shakado S; Sakisaka S; Hirai F
    Curr Oncol; 2022 Jul; 29(7):4799-4810. PubMed ID: 35877241
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Single or combined immune checkpoint inhibitors compared to first-line platinum-based chemotherapy with or without bevacizumab for people with advanced non-small cell lung cancer.
    Ferrara R; Imbimbo M; Malouf R; Paget-Bailly S; Calais F; Marchal C; Westeel V
    Cochrane Database Syst Rev; 2020 Dec; 12(12):CD013257. PubMed ID: 33316104
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and Safety of Lenvatinib After Progression on First-line Atezolizumab Plus Bevacizumab Treatment in Advanced Hepatocellular Carcinoma Patients.
    Chen YH; Chen YY; Wang JH; Hung CH
    Anticancer Res; 2023 Mar; 43(3):1377-1384. PubMed ID: 36854513
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Single or combined immune checkpoint inhibitors compared to first-line platinum-based chemotherapy with or without bevacizumab for people with advanced non-small cell lung cancer.
    Ferrara R; Imbimbo M; Malouf R; Paget-Bailly S; Calais F; Marchal C; Westeel V
    Cochrane Database Syst Rev; 2021 Apr; 4(4):CD013257. PubMed ID: 33930176
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Initial Experience of Atezolizumab Plus Bevacizumab for Unresectable Hepatocellular Carcinoma in Real-World Clinical Practice.
    Iwamoto H; Shimose S; Noda Y; Shirono T; Niizeki T; Nakano M; Okamura S; Kamachi N; Suzuki H; Sakai M; Kajiwara A; Itano S; Tanaka M; Yamaguchi T; Kuromatsu R; Koga H; Torimura T; On Behalf Of The Kurume Liver Cancer Study Group Of Japan
    Cancers (Basel); 2021 Jun; 13(11):. PubMed ID: 34205099
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Early Changes in Alpha-Fetoprotein Are a Useful Predictor of Efficacy of Atezolizumab plus Bevacizumab Treatment in Patients with Advanced Hepatocellular Carcinoma.
    Kuzuya T; Kawabe N; Hashimoto S; Miyahara R; Sawaki A; Nakano T; Nakaoka K; Tanaka H; Miyachi Y; Mii A; Kamejima S; Takahara T; Kato Y; Sugioka A; Hirooka Y
    Oncology; 2022; 100(1):12-21. PubMed ID: 34731863
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Predictive biomarkers of survival in patients with advanced hepatocellular carcinoma receiving atezolizumab plus bevacizumab treatment.
    Chon YE; Cheon J; Kim H; Kang B; Ha Y; Kim DY; Hwang SG; Chon HJ; Kim BK
    Cancer Med; 2023 Feb; 12(3):2731-2738. PubMed ID: 35997637
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and safety of atezolizumab plus bevacizumab combined with hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma.
    Xin Y; Cao F; Yang H; Zhang X; Chen Y; Cao X; Zhou X; Li X; Zhou J
    Front Immunol; 2022; 13():929141. PubMed ID: 35990634
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Baseline ALBI score and early variation of serum AFP predicts outcomes in patients with HCC treated by atezolizumab-bevacizumab.
    Campani C; Bamba-Funck J; Campion B; Sidali S; Blaise L; Ganne-Carrié N; Demory A; Sutter O; Larrey E; Evain M; Ghannouchi H; Wagner M; Marra F; Sutton A; Allaire M; Nault JC
    Liver Int; 2023 Mar; 43(3):708-717. PubMed ID: 36444741
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Current Role of Atezolizumab Plus Bevacizumab Therapy in the Sequential Treatment of Unresectable Hepatocellular Carcinoma.
    Komatsu S; Yano Y; Fujishima Y; Ishida J; Kido M; Kuramitsu K; Yamamoto A; Goto T; Yanagimoto H; Toyama H; Ueda Y; Kodama Y; Fukumoto T
    Anticancer Res; 2022 Mar; 42(3):1403-1412. PubMed ID: 35220233
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical Outcomes With Lenvatinib in Patients Previously Treated With Atezolizumab/Bevacizumab for Advanced Hepatocellular Carcinoma.
    Muto H; Kuzuya T; Kawabe N; Ohno E; Funasaka K; Nagasaka M; Nakagawa Y; Miyahara R; Shibata T; Hashimoto S; Katano Y; Hirooka Y
    Anticancer Res; 2023 Oct; 43(10):4673-4682. PubMed ID: 37772587
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Outcome of Atezolizumab Plus Bevacizumab Combination Therapy in High-Risk Patients with Advanced Hepatocellular Carcinoma.
    Hwang SY; Woo HY; Heo J; Kim HJ; Park YJ; Yi KY; Lee YR; Park SY; Chung WJ; Jang BK; Tak WY
    Cancers (Basel); 2024 Feb; 16(4):. PubMed ID: 38398229
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Association between Adverse Events and Prognosis in Patients with Hepatocellular Carcinoma Treated with Atezolizumab Plus Bevacizumab: A Multicenter Retrospective Study.
    Shimose S; Iwamoto H; Tanaka M; Niizeki T; Kajiwara M; Itano S; Moriyama E; Shirono T; Noda Y; Kamachi N; Nakano M; Kuromatsu R; Koga H; Kawaguchi T
    Cancers (Basel); 2022 Sep; 14(17):. PubMed ID: 36077816
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Atezolizumab plus Bevacizumab versus Sorafenib in the Chinese Subpopulation with Unresectable Hepatocellular Carcinoma: Phase 3 Randomized, Open-Label IMbrave150 Study.
    Qin S; Ren Z; Feng YH; Yau T; Wang B; Zhao H; Bai Y; Gu S; Li L; Hernandez S; Xu DZ; Mulla S; Wang Y; Shao H; Cheng AL
    Liver Cancer; 2021 Jul; 10(4):296-308. PubMed ID: 34414118
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Reproducible safety and efficacy of atezolizumab plus bevacizumab for HCC in clinical practice: Results of the AB-real study.
    Fulgenzi CAM; Cheon J; D'Alessio A; Nishida N; Ang C; Marron TU; Wu L; Saeed A; Wietharn B; Cammarota A; Pressiani T; Personeni N; Pinter M; Scheiner B; Balcar L; Napolitano A; Huang YH; Phen S; Naqash AR; Vivaldi C; Salani F; Masi G; Bettinger D; Vogel A; Schönlein M; von Felden J; Schulze K; Wege H; Galle PR; Kudo M; Rimassa L; Singal AG; Sharma R; Cortellini A; Gaillard VE; Chon HJ; Pinato DJ
    Eur J Cancer; 2022 Nov; 175():204-213. PubMed ID: 36148739
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Updated efficacy and safety data from IMbrave150: Atezolizumab plus bevacizumab vs. sorafenib for unresectable hepatocellular carcinoma.
    Cheng AL; Qin S; Ikeda M; Galle PR; Ducreux M; Kim TY; Lim HY; Kudo M; Breder V; Merle P; Kaseb AO; Li D; Verret W; Ma N; Nicholas A; Wang Y; Li L; Zhu AX; Finn RS
    J Hepatol; 2022 Apr; 76(4):862-873. PubMed ID: 34902530
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.